Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

E. Robson, Mark; Im, Seock‐Ah; Senkus, Elżbieta; Xu, Binghe; M. Domchek, Susan; Masuda, Norikazu; Delaloge, Suzette; Li, Wěi; Tung, Nadine; Armstrong, Anne; Wu, Wenting; Goessl, Carsten; Runswick, Sarah; Conte, PierFranco

doi:10.1056/nejmoa1706450

Public

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Published in New England Journal of Medicine • Jun 4, 2017

Authors:

Mark E. Robson

Seock‐Ah Im

Elżbieta Senkus

Abstract

BACKGROUND: Olaparib is an oral poly(adenosine diphosphate-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation. METHODS: We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compar...

Subject

Olaparib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!